MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen will work together on a project to develop a therapeutic against a novel target, soluble CTLA-4. The University of Aberdeen have already shown that antibodies against this target behave to activate the immune system in a way that may help fight cancers. Now, in collaboration with the University, MRC Technology will go on to develop a clinical antibody and demonstrate its effectiveness at treating cancer.